EP3212290A4 - Serpin fusion polypeptides and methods of use thereof - Google Patents
Serpin fusion polypeptides and methods of use thereof Download PDFInfo
- Publication number
- EP3212290A4 EP3212290A4 EP15854670.5A EP15854670A EP3212290A4 EP 3212290 A4 EP3212290 A4 EP 3212290A4 EP 15854670 A EP15854670 A EP 15854670A EP 3212290 A4 EP3212290 A4 EP 3212290A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- fusion polypeptides
- serpin fusion
- serpin
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008847 Serpin Human genes 0.000 title 1
- 108050000761 Serpin Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000003001 serine protease inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/524,832 US10400029B2 (en) | 2011-06-28 | 2014-10-27 | Serpin fusion polypeptides and methods of use thereof |
PCT/US2015/057533 WO2016069574A1 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3212290A1 EP3212290A1 (en) | 2017-09-06 |
EP3212290A4 true EP3212290A4 (en) | 2019-01-23 |
Family
ID=55858243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15854670.5A Pending EP3212290A4 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3212290A4 (en) |
JP (2) | JP6737781B2 (en) |
KR (2) | KR20240005109A (en) |
CN (2) | CN107206257A (en) |
AU (3) | AU2015339507B2 (en) |
BR (1) | BR112017008525A2 (en) |
CA (1) | CA2965151A1 (en) |
HK (1) | HK1244460A1 (en) |
IL (2) | IL251799B2 (en) |
MX (2) | MX2017005467A (en) |
RU (1) | RU2746550C2 (en) |
SG (2) | SG11201703390SA (en) |
UA (1) | UA127305C2 (en) |
WO (1) | WO2016069574A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021008200A2 (en) * | 2018-10-29 | 2021-12-14 | Spin Therapeutics Llc | Compositions and methods for alpha-1-antitrypsin disorders |
WO2020097946A1 (en) * | 2018-11-18 | 2020-05-22 | 杭州博虎生物科技有限公司 | Recombinant human interleukin-10 fusion protein and application thereof |
CN112315897A (en) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | Polymer microneedle for treating acute gout attack by inhibiting release of cell inflammatory reaction and preparation method |
WO2022133521A1 (en) * | 2020-12-21 | 2022-06-30 | Macquarie University | Treatment of glaucoma |
GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
US20240139296A1 (en) * | 2021-03-03 | 2024-05-02 | Formycon Ag | Formulations of ace2 fc fusion proteins |
CN113325181A (en) * | 2021-04-25 | 2021-08-31 | 苏州市立医院(北区) | Application of serine protease inhibitor in marker for early warning of sepsis |
CN114874333A (en) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | Growth hormone fusion protein and application thereof |
TW202409072A (en) | 2022-05-16 | 2024-03-01 | 美商英伊布里克斯公司 | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092219A2 (en) * | 2003-04-10 | 2004-10-28 | Protein Design Labs, Inc | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2013003641A2 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
US20130058919A1 (en) * | 2002-03-01 | 2013-03-07 | Xencor, Inc. | Optimized Fc Variants and Methods for their Generation |
WO2014001325A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1161532A1 (en) * | 1999-03-01 | 2001-12-12 | Human Genome Sciences, Inc. | Human serpin proteins |
JP4745230B2 (en) * | 2003-07-18 | 2011-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Inhibitors of serine proteases, in particular HCV NS3-NS4A protease |
DK2520654T3 (en) * | 2003-08-26 | 2017-05-01 | Univ Colorado Regents | Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101027427B1 (en) * | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | Fc VARIANTS WITH INCREASED BINDING TO FcRn |
EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
AU2006280004A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | MCP1 fusions |
EP2307456B1 (en) * | 2008-06-27 | 2014-10-15 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
MX357289B (en) * | 2008-12-19 | 2018-07-04 | Macrogenics Inc | COVALENT DIABODIES and USES THEREOF. |
RS55906B1 (en) * | 2010-12-23 | 2017-09-29 | Janssen Biotech Inc | Active protease-resistant antibody fc mutants |
CA2828289C (en) * | 2011-03-29 | 2020-07-21 | Roche Glycart Ag | Antibody fc variants |
IN2013MN02442A (en) * | 2011-06-28 | 2015-06-12 | Inhibrx Llc | |
EP2802653A4 (en) * | 2012-01-10 | 2015-09-02 | Univ Colorado Regents | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
TW201402611A (en) * | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | Incretin receptor ligand polypeptide Fc-region fusion polypeptides and conjugates with altered Fc-effector function |
ES2602030T3 (en) * | 2012-08-02 | 2017-02-17 | F. Hoffmann-La Roche Ag | Method for producing soluble RFc as fusion of Fc with the Fc region of inert immunoglobulin and uses thereof |
AU2013355120B2 (en) * | 2012-12-05 | 2017-11-09 | Sola Biosciences Llc | Protein expression enhancing polypeptides |
-
2015
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en active Application Filing
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/en active Application Filing
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/en active Search and Examination
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/en active Pending
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/en unknown
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/en active
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/en not_active IP Right Cessation
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/en active Pending
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 UA UAA201705128A patent/UA127305C2/en unknown
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/en active Active
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
-
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/en unknown
-
2018
- 2018-03-05 HK HK18103148.5A patent/HK1244460A1/en unknown
-
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/en active Pending
-
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en not_active Abandoned
-
2024
- 2024-05-29 AU AU2024203586A patent/AU2024203586A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130058919A1 (en) * | 2002-03-01 | 2013-03-07 | Xencor, Inc. | Optimized Fc Variants and Methods for their Generation |
WO2004092219A2 (en) * | 2003-04-10 | 2004-10-28 | Protein Design Labs, Inc | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2013003641A2 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
WO2014001325A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
Non-Patent Citations (1)
Title |
---|
See also references of WO2016069574A1 * |
Also Published As
Publication number | Publication date |
---|---|
IL308589A (en) | 2024-01-01 |
IL251799A0 (en) | 2017-06-29 |
CA2965151A1 (en) | 2016-05-06 |
MX2017005467A (en) | 2017-11-30 |
SG10201903142RA (en) | 2019-05-30 |
RU2017118325A (en) | 2018-11-29 |
AU2021240153A1 (en) | 2021-10-28 |
RU2746550C2 (en) | 2021-04-15 |
WO2016069574A1 (en) | 2016-05-06 |
SG11201703390SA (en) | 2017-05-30 |
AU2024203586A1 (en) | 2024-06-20 |
IL251799B2 (en) | 2024-04-01 |
BR112017008525A2 (en) | 2018-01-30 |
KR20170091096A (en) | 2017-08-08 |
MX2021012047A (en) | 2021-11-03 |
EP3212290A1 (en) | 2017-09-06 |
AU2015339507B2 (en) | 2021-07-01 |
JP2020180157A (en) | 2020-11-05 |
JP2017537888A (en) | 2017-12-21 |
IL251799B1 (en) | 2023-12-01 |
UA127305C2 (en) | 2023-07-19 |
HK1244460A1 (en) | 2018-08-10 |
RU2017118325A3 (en) | 2019-03-21 |
KR20240005109A (en) | 2024-01-11 |
CN107206257A (en) | 2017-09-26 |
CN114316068A (en) | 2022-04-12 |
JP6737781B2 (en) | 2020-08-12 |
AU2015339507A1 (en) | 2017-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275307B (en) | Syntac polypeptides and uses thereof | |
HRP20190028T1 (en) | Interleukin-2 fusion proteins and uses thereof | |
EP3390624A4 (en) | Modified site-directed modifying polypeptides and methods of use thereof | |
EP3148573A4 (en) | Ox40l fusion proteins and uses thereof | |
EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
EP3455263A4 (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
EP3154582A4 (en) | Anti-tnf-alpha glycoantibodies and uses thereof | |
HK1244460A1 (en) | Serpin fusion polypeptides and methods of use thereof | |
EP3154972A4 (en) | Azamophinan derivatives and use thereof | |
EP3349851A4 (en) | Light-responsive polypeptides and methods of use thereof | |
EP3240576A4 (en) | Methods of transdifferentiation and methods of use thereof | |
HK1243443A1 (en) | C1 esterase inhibitor fusion proteins and uses thereof | |
EP3107569A4 (en) | Anti-acth antibodies and use thereof | |
EP3129094A4 (en) | Bougie and method of making and using same | |
EP3199543A4 (en) | Novel peptide and use thereof | |
EP3092248A4 (en) | Fusion polypeptides and methods of use | |
EP3407871A4 (en) | Alk polypeptides and methods of use thereof | |
EP3193755A4 (en) | Fusion systems and methods of assembly and use | |
GB201410031D0 (en) | Polypeptides and uses thereof | |
EP3237452A4 (en) | Fusion proteins and methods thereof | |
EP3322736A4 (en) | Fusion polypeptides and methods of use | |
EP3325499A4 (en) | Novel peptide and use thereof | |
EP3209697A4 (en) | Fn14-binding proteins and uses thereof | |
EP3204003A4 (en) | Selenosugars and therapeutic uses thereof | |
EP3166406A4 (en) | Cytokine-chitosan bioconjugates and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170511 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1244460 Country of ref document: HK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/24 20060101ALI20180808BHEP Ipc: C07K 14/81 20060101ALI20180808BHEP Ipc: C07K 16/00 20060101ALI20180808BHEP Ipc: A61P 37/00 20060101AFI20180808BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190104 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/00 20060101AFI20181220BHEP Ipc: C07K 16/24 20060101ALI20181220BHEP Ipc: C07K 16/00 20060101ALI20181220BHEP Ipc: C07K 14/81 20060101ALI20181220BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20211104 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INHIBRX, INC. |